Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/56025

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

INVESTIGATING DRUG RESISTANCE OF MYCOBACTERIUM LEPRAE IN THE COMOROS: AN OBSERVATIONAL DEEP-SEQUENCING STUDY
Braet, Sofie Marijke et al. | Date Issued: 2022
Author
Braet, Sofie Marijke
Jouet, Agathe
Aubry, Alexandra
Van Dyck-Lippens, Magalie
Lenoir, Esteban
Assoumani, Younoussa
Baco, Abdallah
Mzembaba, Aboubacar
Cambau, Emmanuelle
Vasconcellos, Sidra Ezidio Gonçalves
Rigouts, Leen
Suffys, Philip Noel
Hasker, Epco
Supply, Philip
Jong, Bouke Catherine de
Affilliation
Ver em NOTAS - Autores e respectivas afiliações.
Abstract
Despite strong leprosy control measures, including effective treatment, leprosy persists in the Comoros. As of May, 2022, no resistance to anti-leprosy drugs had been reported, but there are no nationally representative data. Post-exposure prophylaxis (PEP) with rifampicin is offered to contacts of patients with leprosy. We aimed to conduct a countrywide drug resistance survey and investigate whether PEP led to the emergence of drug resistance in patients with leprosy.
Keywords in Portuguese
Mycobacterium leprae
Investigando a resistência a drogas
Comoros
Estudo observacional de sequenciamento profundo
 
Keywords
Mycobacterium leprae
Investigating drug resistance
Comoros
Observational deep-sequencing study
 
Publisher
Elsevier Ltd.
Citation
BRAET, Sofie Marijike et al. Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. Lancet Microbe, 3: e693-700, p. 1 - 8, July 2022.
DOI
10.1016/ S2666-5247(22)00117-3
ISSN
2666-5247
Notes
Lancet Microbe 2022 - 3: e693–700. Ver Autores e respectivas Afiliações: Institution of Tropical Medicine, Antwerp, Belgium (S Marijke Braet MSc, M Van Dyck-Lippens BSc, Prof L Rigouts PhD, Prof E Hasker PhD, B C de Jong MD); Department of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium (S Marijke Braet, Prof L Rigouts); Research Foundation Flanders, Brussels, Belgium (S Marijke Braet); GenoScreen, Lille, France (A Jouet PhD, E Lenoir MSc); Sorbonne Université, INSERM, Centre d’Immunologie et des Maladies Infectieuses (Prof A Aubry PhD) and Centre National de Référence des Mycobactéries et de la Résistance des mycobactéries aux antituberculeux (Prof A Aubry), Paris, France; Damien Foundation, Brussels, Belgium (Y Assoumani MD, A Baco MSc); National Tuberculosis and Leprosy Control Program, Moroni, Comoros (A Mzembaba MD); Inserm UMR 1137 Iame, service de mycobactériologie spécialisée et de référence, APHP GHU Paris Nord, Hôpital Bichat, Paris, France (Prof E Cambau PhD); Laboratory of Molecular Biology applied to Mycobacteria, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil (S E G Vasconcellos PhD, P N Suffys PhD); U1019-UMR 9017-CIIL, Université de Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Lille, France (Prof P Supply PhD)